- PR Newswire•yesterdayBioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is part of a research collaboration between MSD and MD Anderson Cancer Center. The open-label, single center, single-arm Phase 2a study aims to evaluate the potential of BL-8040 in combination with KEYTRUDA in pancreatic cancer and focuses on the mechanism-of-action by which both drugs might synergize.
- PR Newswire•14 days ago
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Philip Serlin, will be presenting at the Biotech Showcase 2017 Conference being held in San Francisco, CA. The BioLineRx presentation is scheduled to start at 2:30 pm PST on Tuesday, January 10, 2017. A live audio webcast of the presentation will be available online at BioLineRx's investor web page.
- PR Newswire•last monthBioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as detailed mechanism-of-action data, for BL-8040, the Company's leading oncology platform at the ongoing 58th American Society of Hematology (ASH) Annual Meeting and Exhibition in San Diego, California. As previously announced, in an oral presentation at 10:30am PST today, entitled, "The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and their Terminal Differentiation by Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of miR-15a/16-1 Expression," BioLineRx reports detailed data on the mechanism-of-action by which BL-8040 directly induces apoptosis of AML cells.
BLRX.TA : Summary for BIOLINE RX LTD ILS0.01 - Yahoo Finance
BioLine Rx Ltd (BLRX.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Add to watchlist
|Bid||360.50 x 255900|
|Ask||360.70 x 42900|
|Day's Range||361.00 - 373.00|
|52 Week Range||2.88 - 373.00|
|PE Ratio (TTM)||-1,332.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|